MetaVia Expands IP Portfolio to Advance Cardiometabolic Drug Vanoglipel and Address Metabolic Diseases

MetaVia Strengthens Intellectual Property Position to Advance Cardiometabolic Solutions

MetaVia Inc., a clinical-stage biotechnology company based in Cambridge, Massachusetts, announces the expansion of its global intellectual property portfolio, critical to the development of its lead candidate, vanoglipel (DA-1241). This novel G-protein-coupled receptor 119 (GPR119) agonist targets cardiometabolic diseases, specifically addressing conditions such as Metabolic Dysfunction-Associated Steatohepatitis (MASH) and type 2 diabetes. The strength of MetaVia's intellectual property is underscored by the acquisition of 48 granted and pending patents in key market regions, including the U.S., Europe, Japan, and China. This extensive patent protection is set to secure the company’s interests in vanoglipel and its manufacturing processes until potentially 2035.

The importance of this intellectual property portfolio cannot be overstated, as highlighted by Hyung Heon Kim, President and CEO of MetaVia. A strong patent foundation not only fortifies the company's market position but also enhances the long-term value of vanoglipel. By exclusively licensing these patents from Dong-A ST Co., Ltd., MetaVia is positioned to leverage its advancements in treating serious metabolic conditions. The activation of GPR119 in the gut by vanoglipel stimulates the release of critical gut peptides that regulate glucose and lipid metabolism, resulting in significant weight loss and metabolic improvement. Preclinical studies have shown promising results, demonstrating vanoglipel's efficacy in reducing hepatic steatosis, inflammation, and fibrosis while enhancing glucose control in various animal models.

The favorable outcomes from Phase 1a, 1b, and 2a clinical trials add another layer of optimism regarding vanoglipel’s tolerability and effectiveness. MetaVia's commitment to addressing obesity and other metabolic diseases is further displayed through its development of DA-1726, a complementary compound aimed at obesity treatment. This strategic focus not only reinforces MetaVia’s dedication to innovative therapies but also reflects a robust pipeline poised to meet growing clinical needs in the cardiometabolic sector.

In conjunction with its intellectual property advancements, MetaVia's clinical results bolster its standing as a leader in the biotechnology industry. The ongoing research and development efforts signify a promising horizon for patients suffering from metabolic conditions. By combining a solid patent strategy with compelling clinical data, MetaVia is well-positioned to transform its scientific innovations into tangible therapeutic options that can significantly improve quality of life for individuals with cardiometabolic diseases.